• Bioheart Inc., of Sunrise, Fla., established a $3 million equity financing facility with an investor, under which Bioheart may choose to sell common stock to the investor over the next two years. Proceeds will be used for clinical trials of Bioheart's muscle-derived cell therapy, MyoCell, for chronic heart failure.

• CoDa Therapeutics Inc., of San Diego, received a $6 million term loan from Square 1 Bank. The wound healing and tissue repair company previously closed a $19.2 million Series B financing in April. (See BioWorld Today, April 19, 2011.)

• Unigene Laboratories Inc., of Boonton, N.J., sold $1.5 million of stock to Claus Christiansen, chairman of Nordic Bioscience AS, through his Den Danske Forskningsfond foundation. The foundation has an option to purchase an additional $1.5 million by year-end and up to $3 million in the first half of 2012. Separately, Unigene and Nordic entered a diabetes-focused joint venture on Friday. (See related item, p. 8.)